Whitehawk Therapeutics (WHWK) Price & Analysis

Compare

498 Followers

WHWK Stock Chart & Stats

$2.85

Market closed

$2.85

Day’s Range― - ―

52-Week Range$1.39 - $3.77

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.35M

Market Cap

$134.32M

Enterprise Value$100.63M

Total Cash (Recent Filing)$177.20M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)21.0

Beta0.76

Next Earnings

Mar 12, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding47,128,360

10 Day Avg. Volume9,835,549

30 Day Avg. Volume3,352,856

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.63

Price to Sales (P/S)3.29

P/FCF Ratio-1.40

Enterprise Value/Market Cap0.75

Enterprise Value/Revenue4.66

Enterprise Value/Gross Profit-19.72

Enterprise Value/Ebitda-1.04

Forecast

1Y Price Target

$6.50

Price Target Upside128.07% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst Valuation And CoverageAnalysts initiating coverage with a buy rating describe the company as undervalued as a pure-play next-generation topoisomerase I inhibitor ADC developer, suggesting upside from upcoming catalysts and peer program readthroughs.

Pipeline PositioningAnalyst views Whitehawk as strategically positioned to attain best-in-class status in the next-generation antibody-drug conjugate space by focusing on targets with clinical validation and limited competition, potentially expanding market share.

Preclinical DifferentiationPreclinical studies indicate Whitehawk's ADCs demonstrate a wider therapeutic window, enhanced molecule stability, and improved tolerability versus approved therapies, supporting potential clinical differentiation.

Bears Say

Regulatory And Development UncertaintySafety concerns related to mechanism-based toxicities could complicate regulatory review and slow clinical progress, increasing uncertainty around approval timelines and commercialization prospects.

Safety RiskAnalyst flags significant safety risks tied to the topoisomerase I mechanism, including severe blood toxicities and interstitial lung disease, making safety outcomes a pivotal factor for investor confidence.

Whitehawk Therapeutics News

Whitehawk Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Whitehawk Therapeutics (WHWK) with an Outperform rating and $6 price target The firm sees...

13d ago

WHWK

Whitehawk Therapeutics says FDA clears IND application for HWK-007

Whitehawk Therapeutics (WHWK) announced that the U.S. FDA has cleared the Investigational New Drug application for HWK-007, its...

1M ago

WHWK

CWAN, HTBK, OVID, MCFT, WHWK Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CWAN) ), ( ($HTBK) ), ( ($OVID) ), ( ($MCFT)...

2M ago

CWAN

HTBK

Whitehawk Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Soumit Roy initiated coverage of Whitehawk Therapeutics (WHWK) with a Buy rating and $7 price target...

2M ago

WHWK

Whitehawk Therapeutics appoints Dugan as Chief Medical Officer

Whitehawk Therapeutics (WHWK) announced the appointment of Margaret Dugan, MD, as Chief Medical Officer, CMO. Dr. Dugan brings...

3M ago

WHWK

Whitehawk Therapeutics Reports Q3 2025 Financial Results

Aadi Bioscience, Inc. ( ($WHWK) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

WHWK

Cautious Optimism for Whitehawk Therapeutics: Balancing Innovation with Risk in Next-Gen ADCs

TD Cowen analyst Tara Bancroft has maintained their neutral stance on WHWK stock, giving a Hold rating today....

3M ago

WHWK

Cautious Outlook on Whitehawk Therapeutics Amid Financial Challenges and Clinical Uncertainties

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on WHWK stock, giving a Hold rating on...

3M ago

WHWK

Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year

Reports Q3 revenue $0, consensus $33.33M. Cash, cash equivalents and short-term investments as of September 30, 2025, were...

3M ago

WHWK

Tempus AI enters pact with Whitehawk Therapeutics to advance oncology research

Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK). The collaboration aims to leverage Tempus’ proprietary...

4M ago

TEM

WHWK

Whitehawk Therapeutics Advances ADC Portfolio Amid Financial Growth

Aadi Bioscience, Inc. ( ($WHWK) ) has released its Q2 earnings. Here is a breakdown of the information...

6M ago

WHWK

Cautious Optimism for Whitehawk Therapeutics Amid Strategic ADC Advancements

TD Cowen analyst Tara Bancroft has maintained their neutral stance on WHWK stock, giving a Hold rating on...

6M ago

WHWK

Whitehawk Therapeutics Elects Directors at Annual Meeting

Whitehawk Therapeutics ( ($WHWK) ) just unveiled an update. Whitehawk Therapeutics, Inc. held its annual meeting of stockholders...

8M ago

WHWK

Whitehawk Therapeutics Reports Strong Q1 2025 Results

Aadi Bioscience, Inc. ( ($WHWK) ) has released its Q1 earnings. Here is a breakdown of the information...

9M ago

WHWK

WHWK FAQ

What was Whitehawk Therapeutics’s price range in the past 12 months?

Whitehawk Therapeutics lowest stock price was $1.39 and its highest was $3.77 in the past 12 months.

What is Whitehawk Therapeutics’s market cap?

Whitehawk Therapeutics’s market cap is $134.32M.

When is Whitehawk Therapeutics’s upcoming earnings report date?

Whitehawk Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 22 days.

How were Whitehawk Therapeutics’s earnings last quarter?

Whitehawk Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of $0.067 by -$0.327.

Is Whitehawk Therapeutics overvalued?

According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Whitehawk Therapeutics pay dividends?

Whitehawk Therapeutics does not currently pay dividends.

What is Whitehawk Therapeutics’s EPS estimate?

Whitehawk Therapeutics’s EPS estimate is -0.48.

How many shares outstanding does Whitehawk Therapeutics have?

Whitehawk Therapeutics has 47,128,360 shares outstanding.

What happened to Whitehawk Therapeutics’s price movement after its last earnings report?

Whitehawk Therapeutics reported an EPS of -$0.26 in its last earnings report, missing expectations of $0.067. Following the earnings report the stock price went down -6.667%.

Which hedge fund is a major shareholder of Whitehawk Therapeutics?

Currently, no hedge funds are holding shares in WHWK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Whitehawk Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-13.82%

Trailing 12-Months

Asset Growth

77.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Whitehawk Therapeutics

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

Whitehawk Therapeutics (WHWK) Earnings & Revenues

Historic Earnings Reports

WHWK Stock 12 Month Forecast

Average Price Target

$6.50

▲(128.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,3.1969230769230768,3.5138461538461536,3.8307692307692305,4.147692307692307,4.464615384615384,4.781538461538462,5.098461538461539,5.415384615384616,5.7323076923076925,6.049230769230769,6.366153846153846,6.683076923076923,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,3.1584615384615384,3.436923076923077,3.7153846153846155,3.993846153846154,4.272307692307693,4.55076923076923,4.829230769230769,5.107692307692307,5.386153846153846,5.664615384615384,5.943076923076923,6.2215384615384615,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,3.12,3.36,3.6,3.84,4.08,4.32,4.5600000000000005,4.8,5.04,5.28,5.52,5.76,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.16,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >